Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19).
暂无分享,去创建一个
S. Matskeplishvili | L. I. Dyachuk | A. Potapenko | V. Sinitsyn | Y. Orlova | V. Mareev | E. Pavlikova | L. Samokhodskaya | E. A. Shatokhina | Z. Akopyan | A. Kamalov | T. Krasnova | E. Seredenina | Y. Mareev | D. A. Asratyan | Y. L. Begrambekova | P. S. Malahov | A. Plisuk | М. A. Agapov | E. M. Mershina | L. Dyachuk | E. Mershina | Y. Begrambekova